ByteDance Spins Off AI Drug Discovery Unit Anew Labs, Secures $290M at $1.5B Valuation

ByteDance Completes Major Fundraising Round for AI Drug Discovery Spin-Off

ByteDance has successfully closed a $290 million fundraising round for Anew Labs, its recently spun-off AI drug discovery unit, achieving a valuation of $1.5 billion in its inaugural external fundraising1

1

. The social media and internet giant, known for TikTok and CapCut, will maintain a 56% stake in the Shanghai-headquartered company following the transaction2

2

. This marks a strategic move by ByteDance to separate its AI-for-science applications from its core social media operations, recognizing that AI-driven drug discovery follows fundamentally different industry logic and management approaches1

1

.

Leading Investors Back Anew Labs' Vision

The fundraising round was led by HSG, formerly known as Sequoia China, alongside IDG Capital and Hillhouse Investment, with 5Y Capital serving as co-lead investor1

1

. Additional participants included Gaorong Ventures, Primavera Venture Partners, and Boyu Capital. The round also attracted strategic backing from SBP Group and the state-backed Shanghai Future Industries Fund, signaling strong confidence in the company's approach to commercializing AI in pharmaceutical development1

1

. The involvement of IDG Capital is particularly noteworthy, as the firm previously employed Liu Kai, who now heads Anew Labs after joining ByteDance in 20212

2

.

Strategic Spin-Off Enables Long-Term Development

The ByteDance spin-off represents the company's first major step toward commercializing its AI-for-science efforts, with approximately 50 core staff members transferring to the new entity along with algorithms, technology platforms, and pipeline assets2

2

. ByteDance's cloud division, Volcano Engine, will continue providing computing power to support Anew Labs' operations2

2

. This separation allows the AI drug discovery unit to pursue its own trajectory while leveraging ByteDance's technological infrastructure. The company operates across multiple locations including Shanghai, Singapore, and San Jose, California, with 36 core team members listed on its website as of May2

2

.

Advanced AI Models Drive Drug Development Pipeline

Anew Labs has developed sophisticated structure-prediction and protein-design models, including Protenix and PXDesign, which form the foundation of its drug discovery platform2

2

. The company currently has four drug candidates in development, with one being an AI-designed IL-17 inhibitor that Chris Li, head of the biology department, presented at the American Association of Immunologists' meeting in Boston in April2

2

. While none of these candidates have received approval yet, the company's AI-driven approach to drug discovery positions it to accelerate the traditionally lengthy pharmaceutical development process. Watch for updates on clinical trial progress and potential partnerships with established pharmaceutical companies as Anew Labs moves toward commercialization. The substantial funding and high-profile investor backing suggest confidence that AI drug discovery could dramatically reduce development timelines and costs in the coming years.